Shallis, Rory M.
Podoltsev, Nikolai A. http://orcid.org/0000-0002-3657-778X
Article History
Received: 11 March 2021
Accepted: 18 May 2021
First Online: 28 May 2021
Declarations
:
: Not applicable.
: All authors consent to publication.
: N.A.P. consulted for and received honoraria from Alexion, Pfizer, Agios Pharmaceuticals, Blueprint Medicines, Incyte, Novartis, Celgene, Bristol-Myers Squib, CTI BioPharma and PharmaEssentia. N.A.P. received research funding (all to the institution) from Boehringer Ingelheim, Astellas Pharma, Daiichi Sankyo, Sunesis Pharmaceuticals, Jazz Pharmaceuticals, Pfizer, Astex Pharmaceuticals, CTI biopharma, Celgene, Genentech, AI Therapeutics, Samus Therapeutics, Arog Pharmaceuticals, Kartos Therapeutics. None of these relationships were related to the development of this manuscript. All other authors report no relevant disclosures/competing interests.